Pharmaceutical and medical products manufacturer Abbott will split the company into two separate, publicly traded entities.

The Abbott Park, Ill.-based firm's $18 billion pharmaceutical business will be spun off, renamed, and led by Richard Gonzalez, currently executive vice president of global pharmaceuticals. Its flagship drugs include Humira, Lupron, Synagis, Kaletra, Creon and Synthroid.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access